MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ
1.980
-0.010
-0.50%
After Hours: 1.980 0 0.00% 16:10 05/22 EDT
OPEN
1.990
PREV CLOSE
1.990
HIGH
2.015
LOW
1.945
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
2.660
52 WEEK LOW
0.4040
MARKET CAP
266.43M
P/E (TTM)
-1.3278
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALXO last week (0511-0515)?
Weekly Report · 4d ago
Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)
TipRanks · 5d ago
Analyst Reiterates Buy on ALX Oncology, Maintains $6 Price Target on De-Risked CD47 Program and Upcoming Catalysts
TipRanks · 05/12 10:35
Alx Oncology Signals Promise, But Validation Looms
TipRanks · 05/12 00:21
Analysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)
TipRanks · 05/11 20:40
Analyst Reiterates Buy on Evorpacept’s Biomarker-Driven Potential, Maintains $4 Price Target
TipRanks · 05/11 10:35
Weekly Report: what happened at ALXO last week (0504-0508)?
Weekly Report · 05/11 09:55
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
Seeking Alpha · 05/09 08:02
More
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Webull offers ALX Oncology Holdings Inc stock information, including NASDAQ: ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.